Bisantrene

Summary

Bisantrene (CHEMBL25336) is a phase-3 clinical-stage small molecule; indicated across 1 condition including acute myeloid leukemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 398.5 Da · C22H22N8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL25336
Name	Bisantrene
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5351322
Molecular formula	C22H22N8
Molecular weight	398.5
InChIKey	NJSMWLQOCQIOPE-OCHFTUDZSA-N

SMILES: C1NC(=NC1)N/N=C/C2=C3C(=C(C4=CC=CC=C24)/C=N/NC5=NCCN5)C=CC=C3

IUPAC name: N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine

Also known as: Bisantrene, Bisantreno, NSC-337766, BISANTRENE, bisantrene

Parent form; salt/anhydrous children: CHEMBL3989424

Patent coverage: 53 distinct patent families (85 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 78 (92%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 15 (assay-derived). Sample: Alpha-2A adrenergic receptor, D(1A) dopamine receptor, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1, Acetylcholinesterase, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, Mu-type opioid receptor, D(3) dopamine receptor, Sodium-dependent dopamine transporter, Adenosine receptor A3, RNA demethylase ALKBH5, NAD(P)H dehydrogenase [quinone] 1.

Bioactivity

ChEMBL activities: 13 potent at pChembl ≥ 5 of 15 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ALKBH5	6.85	IC50	140	nM	CHEMBL_ACT_26037647
ADRA1A	5.83	AC50	1470	nM	CHEMBL_ACT_25218616
HTR1A	5.78	AC50	1650	nM	CHEMBL_ACT_25164751
ADORA3	5.7	AC50	2010	nM	CHEMBL_ACT_25198498
SLC6A4	5.65	AC50	2250	nM	CHEMBL_ACT_25151054
CHRM2	5.56	AC50	2740	nM	CHEMBL_ACT_25195463
ACHE	5.41	AC50	3880	nM	CHEMBL_ACT_25142275
DRD1	5.28	AC50	5240	nM	CHEMBL_ACT_25114937
OPRM1	5.27	AC50	5360	nM	CHEMBL_ACT_25157902
DRD3	5.22	AC50	5960	nM	CHEMBL_ACT_25194258
CHRM1	5.2	AC50	6370	nM	CHEMBL_ACT_25209973
SLC6A2	5.15	AC50	7130	nM	CHEMBL_ACT_25145727
SLC6A3	5.02	AC50	9570	nM	CHEMBL_ACT_25124686

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
acute myeloid leukemia	2	MONDO:0018874	EFO:0000222

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03820908	PHASE2	COMPLETED	Bisantrene for Relapsed /Refractory AML
NCT04989335	PHASE2	UNKNOWN	Bisantrene Combination for Resistant AML

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).